← All trials
NCT05523947
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 26, 2022
- Primary completion
- Jan 31, 2024
- Completion date
- Oct 6, 2026
- First posted
- Sep 1, 2022
- Last posted
- Oct 17, 2022
- Enrollment
- 110
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Yuhan Pharmaceutical CompanyLead sponsor
- University of UlsanOverall official - principal investigator
- Sungkyunkwan UniversityOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
- Yonsei UniversityOverall official - principal investigator
- Southern Oncology Clinical Research UnitOverall official - principal investigator
- Austin HealthOfficial
- Seoul National UniversityOfficial
- Sungkyunkwan UniversityOfficial
- Catholic University of KoreaOfficial
- Cha Medical UniversityOfficial
- Southern Oncology Clinical Research UnitOfficial
- University of UlsanOfficial
- Korea UniversityOfficial
- Yonsei UniversityOfficial
- Harvard UniversityOfficial
- Chonbuk National UniversityOfficial
- Ajou UniversityOfficial
- Vanderbilt UniversityOfficial
- Gyeongsang UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.